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Abstract
The study on lifestyle-intervention and impaired glucose tolerance Maastricht (SLIM) is a 3 years randomised clinical
trial designed to evaluate the effect of a combined diet and physical activity intervention program on glucose tolerance
in a Dutch population at increased risk for developing type 2 diabetes. Here the design of the lifestyle-intervention study
is described and results are presented from the preliminary population screening, conducted between March 1999 and
June 2000. In total, 2820 subjects with an increased risk of having disturbances in glucose homeostasis (i.e. age /40
years and BMI/25 kg/m2 or a family history of diabetes) underwent a first oral glucose tolerance test (OGTT).
Abnormal glucose homeostasis was detected in 826 subjects (30.4%): 226 type 2 diabetes (type 2DM, 8.3%), 215
impaired fasting glucose (IFG, 7.9%) and 385 impaired glucose tolerance (IGT, 14.2%). Both increasing age and BMI
were strongly related to the prevalence of IGT and diabetes. After a second OGTT, 114 subjects with glucose
intolerance and in otherwise good health were eligible for participation in the intervention study (SLIM). The high
prevalence of disturbances in glucose homeostasis observed in the preliminary screening underscore the importance of
early (lifestyle) interventions in those at risk for developing diabetes. SLIM will address this topic in the Dutch
population.
# 2003 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
Type 2 diabetes mellitus is rapidly becoming one
of the main health issues in the 21st century.
Prevalence has increased explosively in the last two
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decades, and global estimates indicate a further
rise from a current 150 million people with
diabetes, to 300 million in 2025 [1,2]. Impaired
glucose tolerance (IGT) is the obligatory transition
state preceding type 2 diabetes. Prevalence of IGT
varies widely between populations, from as low as
2.0% in rural populations to more than 20% in
high-risk populations [3]. The cumulative inci-
dence of type 2 diabetes in subjects with IGT
ranged from 3.6 to 8.7% per year in six prospective
studies [4], and is strongly related to the fasting
and the 2-h plasma glucose concentrations at the
time of IGT recognition [4,5]. The most important
modifiable risk factor for progression from IGT to
diabetes is obesity. Body mass index (BMI) at the
time of IGT recognition is a strong predictor of
progression, independently of fasting and 2-h
blood glucose concentrations [4]. Dietary factors,
especially a high fat intake, are also related to the
risk of conversion from IGT to diabetes [6].
Several recent studies have reported the feasi-
bility and efficacy of interventions to prevent or
delay the progression to type 2 diabetes in subjects
with IGT [7/13]. Acarbose, [13], as well as
metformin [12], have been shown to reduce the
incidence of diabetes in a population with IGT.
Other studies have focused on the potential of
lifestyle changes to reduce the progression rate
from IGT to type 2 diabetes. The Finnish diabetes
prevention study (DPS) [11] and the US diabetes
prevention program (DPP) [12] reported that
weight-loss, changes in dietary intake, and in-
creased physical activity resulted in a 58% reduc-
tion in the incidence of diabetes after a mean
follow-up of only 3 years. Moreover, lifestyle-
intervention was much more effective in reducing
the incidence of diabetes than pharmacological
intervention (i.e. metformin) [12]. It is important
to confirm these observations in different popula-
tions, with a different dietary and physical activity
background, and a different attitude towards
changing lifestyle-habits.
The study on lifestyle-intervention and impaired
glucose tolerance Maastricht (SLIM) is a 3 years
randomised clinical trial designed to evaluate the
effect of a combined diet and physical activity
intervention program on glucose tolerance in a
Dutch population at increased risk for developing
type 2 diabetes. Furthermore, we will consider
changes in anthropometric measurements, aerobic
capacity and cardiovascular risk factors. Addi-
tional measurements will be performed in sub-
groups of the study population in a search for
underlying mechanisms.
The objective of this report is to describe the
design of the lifestyle-intervention study and to
evaluate the results of the preliminary population
screening, from which the subjects were recruited
for the intervention study. Data are presented
about the prevalence of disturbances in glucose
homeostasis in a middle-aged Dutch population.
2. Study design and methods
SLIM is designed to study whether a diet/
physical activity intervention program can im-
prove glucose tolerance in subjects with a high
risk for developing type 2 diabetes mellitus. The
total duration of the study is 3 years. The medical
ethical review committee of Maastricht University
approved the study protocol, and all subjects gave
their written informed consent before the start of
the study.
2.1. Recruitment of subjects
The recruitment period started in March 1999
and was completed at the end of May 2000.
2.1.1. Preliminary screening
Subjects with an increased risk for glucose
intolerance, i.e. those of age /40 years and a
family history of diabetes or a BMI/25 kg/m2,
were selected from a large existing cohort, mon-
itoring health and disease in the general popula-
tion [14], and invited to undergo a standard oral
glucose tolerance test (OGTT) (glucose load 75 g)
[15]. Blood glucose was measured in capillary
blood using the Glucometer Elite (Bayer, Zurich,
Schweiz). Furthermore, body weight was mea-
sured, without wearing shoes and jackets. Subjects
with known diabetes, or those with fasting glucose
values /8.5 mmol/l did not participate in the
OGTT.
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2.1.2. Second OGTT
Those subjects with a 2-h blood glucose con-
centration /7.8 mmol/l at the preliminary screen-
ing and which were otherwise in good health (i.e.
no history of cardiovascular disease, or any
(chronic) disease or medication use that makes
participation in a lifestyle intervention program
impossible) were invited for a second OGTT.
During this second OGTT, glucose tolerance was
measured in venous plasma. Furthermore a med-
ical history was taken, a physical examination was
performed and several additional measurements
were performed (see Section 2.3, below).
2.1.3. Final recruitment
For definitive inclusion in the lifestyle-interven-
tion study, mean 2-h glucose concentration of both
OGTTs had to be between 7.8 and 12.5 mmol/l,
together with a fasting glucose concentration of
less than 7.8 mmol/l. Other inclusion and exclusion
criteria for participation in the intervention study
are indicated in Table 1. To follow changes in
glucose tolerance over time, data obtained by the
second (venous) OGTT were used as baseline
values.
After final recruitment, subjects were rando-
mised to two study groups, the lifestyle interven-
tion group or the control group. Randomisation
was carried out with stratification for sex and
mean 2 h-plasma glucose concentration.
Based on the preliminary results after 1 year of
the Finnish DPS [16], we calculated that 50/60
subjects per group would be sufficient to detect a
1.0 mmol/l difference in the 2-h glucose concentra-
tion between groups.
2.2. Lifestyle-intervention program
The intervention program consists of a dietary
and physical activity part.
2.2.1. Dietary intervention
Dietary recommendations are based on the
Dutch guidelines for a healthy diet (Dutch Nutri-
tion Council, 1992, see Table 2). Participants are
encouraged to stop smoking and, if necessary, to
reduce alcohol intake. Dietary advice is given at
regular intervals by a skilled dietician on an
individual basis after consideration of a 3 days
food record (see Table 2). A body weight loss of
5/7% is the objective. If subjects do not loose
weight on this regimen during the first year, mild
energy restriction is prescribed during the second
year. No very-low calorie diet or dietary products
are used to encourage weight loss.
2.2.2. Exercise intervention
Subjects are encouraged to increase their level of
physical activity to at least 30 min of moderate
physical activity a day for at least 5 days a week
[17]. Individual advice is given on how to increase
daily physical activity (walking, cycling, swim-
ming), and goals are set. Furthermore, subjects
are encouraged to participate in an exercise
program, especially designed for this study, in-
cluding components of aerobic exercise training
and components of resistance training [18]. Sub-
jects have free access to these training sessions, and
are stimulated to participate for at least 1 h a
week. Participation in the exercise sessions is
recorded.
2.2.3. Control group
Subjects in the control group are given, oral and
written information, about the beneficial effects of
a healthy diet, weight loss and increased physical
activity, whereas no individual advice or programs
are provided. No additional appointments are
Table 1
Inclusion and exclusion criteria for the lifestyle-intervention
study (SLIM)
Inclusion
criteria
Mean 2-h blood glucose ]/7.8 and 5/12.5 mmol/l
Mean fasting blood glucose 5/7.8 mmol/l
Caucasian
Age 40/70 years
Exclusion
criteria
Known diabetes mellitus
Mean 2-h blood glucose /12.5 mmol/lMean
fasting blood glucose /7.8 mmol/l
Any chronic illness that makes 5-years survival
improbable, or that interferes with glucose
tolerance, or that makes participation in a
lifestyle-intervention impossible
Medication known to interfere with glucose
tolerance
Participation in a regular vigorous exercise
and/or diet program
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scheduled, apart from the annual visits for follow-
up measurements.
2.3. Measurements
At the start of the study, and every year there-
after several measurements are performed, in both
the intervention and control group.
2.3.1. Laboratory assessments
A standard OGTT is performed every year,
according to the guidelines described by the WHO
[15]. Venous blood samples are immediately cen-
trifuged and plasma is frozen at /80 8C until
analysis. Plasma glucose and FFA concentrations
are measured using a standard enzymatic techni-
ques (Glucose HK 125, ABX diagnostics, Mont-
pellier, France; FFA-C test kit, Wako Chemicals,
Neuss, Germany, respectively). Plasma insulin
concentration is measured with an ELISA assay
(Mercodia, Uppsala, Sweden) which shows no
cross-reactivity with pro-insulin. Glycated haemo-
globin (HbA1c) is determined with the HPLC
technique (reference value for our laboratory
4.4/6.2%). Insulin sensitivity is estimated with
the HOMA-index and insulin secretion with the
insulinogenic index 30? (Insulin30/Insulin0)/(glu-
cose 30/glucose0) [19]. Blood lipids are measured
with standard enzymatic techniques in fasting
serum samples (triglycerides: Sigma, St. Louis,
USA; cholesterol: cholesterol 100, ABX diagnos-
tics; HDL: HDL-C Roche, Indianapolis, USA).
Table 2
Details of the dietary intervention
Dietary guidelines
Carbohydrates:
Fat:
Proteins:
Fiber:
9/55% energy
Maximum 15/25% energy mono- and disaccharides
30/35% energy
5/10% energy saturated fatty acids
B/33 mg/MJ cholesterol, maximal 300 mg a day
10/15% energy
9/0.8 g/kg bodyweight
/3 g/MJ a day
Visit Time Visit and topic
1 0 Baseline visit
2 4/6 weeks Discussion baseline food-record
3 3 months ‘Fat’
4 6 months ‘Carbohydrates’
5 9 months Group-session: ‘label-reading’ and ‘novel foods’
6 12 months 1-year meeting
7 15 months ‘Artificial sweeteners’
8 18 months ‘Special occasions, e.g. a party’
9 21 months Group session: ‘a dietary game’
10 24 months 2-year meeting
11 27 months ‘Vegetarian food’
12 30 months ‘Vitamins and minerals’
13 33 months Group-session: ‘lifestyle and diabetes’
14 36 months 3-year meeting
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LDL cholesterol is calculated according to the
formula of Friedewald [20].
2.3.2. Anthropometry
Body weight is measured on an electronical
scale. BMI is calculated as the ratio of weight
and height squared (kg/m2). Skinfold measure-
ments are performed to calculate fat mass, fat free
mass and body fat percentage [21]. Waist circum-
ference (waist) is measured at the level midway
between the lowest rib and the iliacal crest. Hip
circumference is measured as the maximum cir-
cumference over the buttocks. Sagittal and trans-
verse abdominal diameter are measured with the
subject in a recumbent position, at the level of the
iliacal crest using a sliding beam calliper.
2.3.3. Maximal aerobic capacity
To evaluate changes in aerobic fitness, an
incremental exhaustive exercise test is performed
on an electronically braked bicycle ergometer
(Lode Excalibur, Groningen, Netherlands). The
test starts at a workload of 0.75 W/kg FFM for 3
min, followed by 3 min at 1.5 W/kg FFM.
Subsequently, workload is increased every 3 min
by 0.5 W/kg FFM until exhaustion. O2 consump-
tion and CO2 production are measured with an
Oxycon-Beta (Mijnhardt, Breda, Netherlands) to
define maximal peak VO2.
2.3.4. Other measurements
At every (annual) visit a physical examination is
performed, including recording a 12-lead resting
ECG. Blood pressure is measured twice on the
right arm with a standard sphygmomanometer,
after at least 10 min of rest. Subjects taking any
blood pressure-lowering medication are asked not
to take these on the morning of the measurements.
A 3 days food record (2 weekdays and 1 weekend
day) is kept at the start of the study and every year
thereafter. Food records are checked by a dietician
and intake of nutrients is calculated with a
computer program according to the Dutch food
table.
2.3.5. Outcome
Primary outcome measure is the change in
glucose tolerance (i.e. 2-h plasma glucose), one of
the most important risk factors for progression to
diabetes [4]. Secondary outcome measures are
changes in fasting plasma glucose concentration,
plasma insulin concentration, insulin resistance,
HbA1c, and changes in body weight, body compo-
sition and VO2max. Furthermore changes in
cardiovascular risk factors are assessed (blood
pressure and blood lipid profile).
2.4. Statistical analysis
Data from the intervention study are analysed
according to the intention-to-treat principle. Dif-
ferences between groups (over time) are analysed
by unpaired t-tests or ANOVA (repeated mea-
sures). The level of significance is set at 0.05.
Results of the preliminary screening were ana-
lysed with ANOVA (differences between cate-
gories) and x2-testing (frequency distribution of
disturbances in glucose homeostasis).
3. Results
In total 6108 subjects were invited to participate
in the preliminary screening. Of those, 2820
subjects were willing to participate in this first
OGTT. Non-response was observed in 3288 cases
(53.8%). Mean age of the non-responders was
55.79/0.1 years, which was significantly lower
than the responders (n/2820; age 56.89/0.1; P -
valueB/0.001). No difference was seen in gender
between responders and non-responders (50.6
male vs. 50.9% male, respectively, P/ns). After
considering the selection criteria, 379 men and
women were invited for the second OGTT, of
whom 177 were willing to participate. Finally, 114
subjects, 64 men and 50 women, were included in
the lifestyle intervention study (SLIM).
From the 2820 subjects participating in the
screening OGTT, 105 were excluded from the
analysis: 48 because of recently diagnosed dia-
betes; 57 because of non-Caucasian ethnicity, non-
fasting state, or incomplete data. Results from the
remaining 2715 subjects are depicted in Table 3.
WHO criteria of 1999 for capillary plasma were
applied, as the glucometer Elite measures glucose
levels equivalent to capillary plasma [15]. Abnor-
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mal glucose homeostasis was detected in 826
subjects (30.4%): 226 subjects with type 2 Diabetes
(type 2DM, 8.3%), 215 with impaired fasting
glucose (IFG, 7.9%) and 385 with impaired
glucose tolerance (IGT, 14.2%). Of the latter
group, almost two-thirds (n/244) had normal
fasting glucose (NFG/IGT) and one-third (n/
141) impaired fasting glucose (IFG/IGT). The
prevalence of type 2 DM and IFG was higher
among men than women. A strong upward trend
for age and BMI was seen from NGT to type 2
DM, with IGT and IFG in between (Table 3).
In Table 4 the prevalence of NGT, IFG, IGT
and type 2 DM is given for age and BMI groups,
for men and women separately. In both men and
women, prevalence of disturbed glucose home-
ostasis increased with age, except for IFG which
reached the highest prevalence in the age group of
55/59 years. In the population of 65 years and
older, only 55.5% of the men and 63.5% of the
Table 3
Results of the screening OGTT
NGT IFG IGT Type 2 DM P -value
Number % (n ) 69.9 (1889) 7.9 (215) 14.2 (385) 8.3 (226)
Sex (% Male) 47.5 61.2 49.1 67.8 B/0.0001
Age (Year) 55.99/0.2 58.89/0.4 57.19/0.5 59.89/0.4 B/0.0001
BMI (kg/m2) 28.09/0.1 29.79/0.3 29.59/0.2 30.69/0.3 B/0.0001
FBG (mmol/l) 5.29/0.1 6.39/0.1 5.89/0.1 7.49/0.1 B/0.0001
2 h BG (mmol/l) 6.59/0.1 6.89/0.1 10.19/0.1 13.09/0.2a B/0.0001
Data are mean9/S.E.M.; n/2715. FBG, fasting blood glucose; 2 h BG, 2-h blood glucose; comparison of frequencies was done by
x2-test.
a Subjects with fasting glucose /8.5 mmol/l did not undergo an OGTT (n/28).
Table 4
Prevalence of type 2 diabetes, IGT, IFG and NGT in the screening population
Men Women
n DM (%) IGT (%) IFG (%) NGT (%) n DM (%) IGT (%) IFG (%) NGT (%)
Age (years )
B/50 289 6.6 8.0 6.2 79.2 254 0.8 9.1 2.4 87.8
50/54 256 7.8 10.2 13.7 68.4 252 2.4 13.9 6.7 77.0
55/59 289 11.1 14.5 12.5 61.9 281 6.8 14.6 7.8 70.8
60/64 301 14.0 16.3 9.0 60.8 322 8.6 15.8 6.8 70.5
]/65 238 16.8 20.6 7.1 55.5 233 10.3 19.7 6.4 63.5
BMI (kg /m2)
B/27 477 6.7 10.5 6.1 76.7 515 3.1 10.1 4.1 82.7
27/30 484 8.9 10.5 9.7 70.9 415 4.1 15.7 5.5 74.7
]/30 412 18.9 21.4 13.8 45.9 412 9.7 19.2 9.2 61.9
Total 1373 11.1 13.8 9.7 65.4 1342 5.4** 14.6 6.1** 73.8**
**, PB/0.001 between sexes (x2-test).
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women had normal glucose homeostasis. In men
and women with a BMI above 30 kg/m2, diabetes
was three times more prevalent and IFG and IGT
were two times more prevalent, compared with
those with a BMI below 27 kg/m2. The prevalence
of newly diagnosed diabetes was almost two times
higher in men than in women in each BMI and age
group. Likewise, IFG was 1.5 times more frequent
in men than in women, especially in the age groups
below 55 years. Additionally, more women were
normoglycaemic than men (PB/0.001).
4. Discussion
4.1. Lifestyle-intervention
The justification of lifestyle-intervention studies
is that they may prevent or postpone the onset of
type 2 diabetes and related complications. Both
the Finnish DPS and the US DPP reported that
changing dietary and physical activity habits
reduce the incidence of diabetes by about 58%
[11,12]. Confirmation of these results in different
populations is important. SLIM will consider this
in a middle-aged Dutch population at increased
risk for diabetes. The Dutch population has a low
prevalence of obesity [22], and Dutch subjects are
known for their relatively high level of physical
activity. In 1997 slightly more than one-half of the
population was, on average, moderately active for
more than half an hour per day [23], compared
with about one-third of US adults [24]. As obesity
and physical activity are important factors asso-
ciated with diabetes, it is important to know
whether lifestyle changes result in a comparable
risk reduction in the Dutch population as in the
Finnish and American population.
Dietary and physical activity intervention stra-
tegies are combined, as earlier reports indicated
that the combination is most effective [25,26]. The
intervention strategy in this randomised study is
based on general public health recommendations
for nutritional intake and physical activity. A
regimen, based on general recommendations, is
much more suitable to prevent diabetes, as it is less
time consuming and much better tolerated than
very intensive intervention programmes. Further-
more, we will perform additional measurements in
small subgroups of the intervention and control
population (n/10 per group) using stable iso-
topes, indirect calorimetry and muscle biopsies.
Since type 2 diabetes and IGT are characterised by
disturbances in skeletal muscle fatty acid uptake
and oxidation [27/29], the question will be ad-
dressed whether changes in glucose tolerance are
accompanied by changes in skeletal muscle fatty
acid metabolism. These additional measurements
could identify some of the mechanisms underlying
the development of insulin resistance and type 2
diabetes mellitus.
4.2. Methodological considerations
Participation rate was relatively low in the
present study, approximately 50%. As subjects
were selected from an ongoing monitoring project
for health and disease, some ‘research-fatigue’
could not be excluded, and this could have led to
some selection bias. Classification of the subjects
was based on a single OGTT (with the glucometer
Elite), and was not confirmed by repeated testing
as recommended. Some misclassification might
have occurred because of the known high intra-
individual variability in glucose levels. However, a
previous Dutch study showed that the prevalence
of IGT and diabetes was not different between the
first and the second test [30]. Only when the
diagnosis was based on meeting classification
criteria at both OGTT’s, did the prevalence
decrease. Finally, we tested the consistency in
classification between measurements made with
the glucometer Elite and measurements made with
a standard enzymatic technique in venous plasma.
Consistency in classification according to the
WHO criteria was good (69%, kappa 0.55, P -
valueB/0.001; n/245; [31]).
4.3. Preliminary screening
The results of the preliminary screening confirm
the high-risk profile of the population under study.
Three out of every ten subjects had disturbed
glucose homeostasis, which is quite comparable
with the results reported in the STOP-NIDDM
trial, which also screened in a high-risk population
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[32]. The prevalence of IGT and newly diagnosed
diabetes in the screening population was higher
than reported in the Dutch Hoorn Study over the
period 1989/1992 (10.3% for IGT and 4.8% for
newly diagnosed diabetes [33]). This may reflect
the world-wide increasing prevalence of distur-
bances in glucose homeostasis [1], and parallels the
increasing prevalence of obesity reported in the
Dutch population [22]. However, in the Hoorn
study the old WHO-criteria (1985) were used.
Since the fasting glucose level for the diagnosis
of diabetes has now been reduced, this could partly
explain the higher prevalence of diabetes in our
study, but not the higher prevalence of IGT.
In line with other populations, the present study
confirmed that IGT is considerably more prevalent
than IFG, and that overlap between the two
categories is limited [3]. This limited overlap points
towards the difference in metabolic background:
IGT is primarily associated with insulin resistance
while IFG is associated with a more pronounced
defect in insulin secretion and endogenous glucose
output [34].
A strong positive relation was observed between
increasing age and prevalence of IGT and dia-
betes. For IFG, the highest prevalence was seen in
middle-aged subjects (aged 55/59 years). This is a
consistent finding in European populations, parti-
cularly among men [3]. The prevalence of distur-
bances in glucose homeostasis was almost 2-fold
higher in the group with a BMI/30 kg/m2
compared with those with a BMIB/30 kg/m2.
This underscores earlier reports, showing dramatic
increases in the relative risk of diabetes in the
highest BMI groups, compared with the lowest
BMI group [35].
Type 2 diabetes is generally more prevalent in
women compared with men [1]. In contrast, we
observed a prevalence of diabetes being two times
higher in males than in females, in all BMI and age
groups. In the Finnmark study [36], BMI was
reported to be a dominant risk factor for both
sexes. In women, however, the relationship was
confounded by other factors such as blood pres-
sure, height, HDL, glucose, smoking and physical
activity. Furthermore, in addition to over-all
adiposity, body fat distribution is an important
risk factor for diabetes [35]. Thus, differences in
other risk factors, beside age and BMI, can
underlie the observed higher prevalence of diabetes
in men in the present study.
4.4. Conclusion
The high prevalence of disturbances in glucose
homeostasis observed in the preliminary screening
underscores the importance of early interventions
in those at risk for developing diabetes. Changes in
dietary habits and physical activity have shown to
reduce the incidence of diabetes. Additional stu-
dies are required to confirm these results in
different populations with a different dietary and
physical activity background. SLIM will address
this question in the Dutch population.
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